Exchange: NASDAQ·Updated 07:34 PM EDT
Upcoming Earnings: Q2 '26

Reports: Aug 12After Hours

Estimated EPS

-$0.56

Estimated Rev

$0M

$AVIR Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.57 down -42.50% YoY • Atea Pharmaceuticals Inc expects to report topline results for its C-BEYOND HCV trial in mid-2026 and C-FORWARD at year-end 2026, targeting March 2027 for NDA submission, with AT-587 entering Phase 1 in mid-2026.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q2 '26
-$0.56
--
--
N/A
Q1 '26
-$0.56
-$0.57
-2.70%
MISSED
Q4 '25
-$0.49
-$0.57
-17.53%
MISSED
Q3 '25
-$0.41
-$0.53
-27.71%
MISSED
Q2 '25
-$0.41
-$0.44
-6.02%
MISSED

Advertisement|Remove ads.